Lastly, since the completion of RIAltO, the therapeutic landscape of CLL has shifted significantly with the introduction of BTK and BCL-2 inhibitors, such that chemoimmunotherapy no longer have a significant role in the treatment of CLL. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.